Clinical Utility of the Paed‐ EQUAL Candida Score in Paediatric Candidemia: A Real‐World Cohort Study
Mycoses · 2026
DOI: 10.1111/myc.70207 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Mycoses, 2026. Verfasst von Kubra Aykac und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Infectious Diseases, Hacettepe University Faculty of Medicine, Ankara, Türkiye. Hauptthemen laut MEDLINE: Candidemia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The Paed‐EQUAL Candida Score was developed to assess adherence to guideline‐recommended management in paediatric candidemia; however, its clinical utility in predicting outcomes remains unclear, particularly in paediatric populations where validation data are scarce.
Methods
We conducted a retrospective observational study including paediatric patients diagnosed with candidemia at a tertiary‐care centre between 2014 and 2024. The Paed‐EQUAL Candida Score was calculated for each patient, and its association with 30‐day and 90‐day mortality was evaluated using ROC curve analysis, and optimal cut‐off values were explored.
Results
A total of 127 paediatric patients with candidemia were included, of whom 17 (13.4%) died within 30 days and 27 (21.3%) within 90 days. Central venous catheter removal was significantly associated with improved survival at both 30 days (76.4% vs. 35.3%, p = 0.001) and 90 days (77% vs. 48.1%, p = 0.007). Higher adherence to Paed‐EQUAL Candida Score components was observed among survivors, with significantly higher median scores in survivors compared to non‐survivors at 30 days (17 [IQR 14–18] vs. 14 [12–16], p = 0.026). However, the score indicated modest discriminative ability for predicting mortality, with an AUC of 0.667 (95% CI 0.577–0.748) for 30‐day mortality and no significant predictive value for 90‐day mortality (AUC 0.594, 95% CI 0.503–0.680).
Conclusion
The Paed‐EQUAL Candida Score demonstrated limited prognostic performance in paediatric candidemia and may have constraints in its ability to support clinical decision‐making, particularly given its modest discriminative capacity. While it remains a potentially useful tool for assessing adherence to quality‐of‐care measures, further refinement or development of paediatric‐specific and outcome‐oriented scoring systems may be needed to improve risk stratification and prediction of clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Infectious Diseases, Hacettepe University Faculty of Medicine, Ankara, Türkiye.
- Department of Pediatric Diseases, Ankara, Turkey, Hacettepe University Faculty of Medicine, Ankara, Türkiye.
- Department of Biostatistics, Hacettepe University Faculty of Medicine, Ankara, Türkiye.
ORCID-Profile: Kubra Aykac, Osman Oguz Demir, Yasemin Ozsurekci
Zitieren
APA
Aykac, K., Sirin, I., Ozdemir, T., Demir, O. O., Kuruc, A. I., Avcı, H., Cengiz, A. B., & Ozsurekci, Y. (2026). Clinical Utility of the Paed‐ EQUAL Candida Score in Paediatric Candidemia: A Real‐World Cohort Study. Mycoses. https://doi.org/10.1111/myc.70207
Vancouver
Aykac K, Sirin I, Ozdemir T, Demir OO, Kuruc AI, Avcı H, et al. Clinical Utility of the Paed‐ EQUAL Candida Score in Paediatric Candidemia: A Real‐World Cohort Study. Mycoses. 2026. doi:10.1111/myc.70207
BibTeX
@article{Aykac2026,
author = {Aykac, Kubra and Sirin, Ilgın and Ozdemir, Turgut and Demir, Osman Oguz and Kuruc, Aylin Irmak and Avcı, Hanife and Cengiz, Ali Bulent and Ozsurekci, Yasemin},
title = {Clinical Utility of the Paed‐ EQUAL Candida Score in Paediatric Candidemia: A Real‐World Cohort Study},
journal = {Mycoses},
year = {2026},
doi = {10.1111/myc.70207}
}
EUVIMED